- Review Article
- Published:
TheINK4a/ARF network in tumour suppression
Nature Reviews Molecular Cell Biologyvolume 2, pages731–737 (2001)Cite this article
7541Accesses
782Citations
15Altmetric
Abstract
The retinoblastoma protein (RB) and p53 transcription factor are regulated by two distinct proteins that are encoded by theINK4a/ARF locus. Genes encoding these four tumour suppressors are disabled, either in whole or in part, in most human cancers. A complex signalling network that interconnects the activities of RB and p53 monitors oncogenic stimuli to provide a cell-autonomous mode of tumour surveillance.
Key Points
The humanINK4a/ARF locus encodes two distinct tumour-suppressor proteins — p16INK4a and p14ARF (p19Arf in the mouse) — in part, through the utilization of alternative reading frames. p16INK4a and p14ARF function by promoting the activities of the retinoblastoma protein (RB) and p53 transcription factor, respectively.
p16INK4a is an inhibitor of the cyclin D-dependent kinases, CDK4 and CDK6, whereas p14ARF antagonizes the function of the p53 negative regulator, HDM2 (Mdm2 in the mouse).
p16INK4a blocks cell cycle progression through two mechanisms. It disrupts and inhibits holoenzyme complexes containing D-type cyclins and either CDK4 or CDK6. It also mobilizes bound Cip/Kip proteins, which indirectly blocks the activities of cyclin E- and A-dependent CDK2.
Although four different INK4 proteins act as potent inhibitors of cyclin D-dependent kinases, p16INK4a plays the most prominent role in tumour suppression, presumably because of its unique pattern of expression.
Selective disruption of eitherInk4a orArf coding sequences in the mouse germ line shows that both genes act as tumor suppressors and have roles in cellular senescence.
Specific combinations of genetic lesions that affect theInk4a andArf genes on homologous chromosomes predispose to many different forms of cancer.
Arf is activated by oncogenic signals, such as Myc overexpression or constitutive Ras activation. By activating p53, p19Arf diverts incipient cancer cells to alternative fates — either to p53-dependent growth arrest or apoptosis.
A complex signalling network — consisting of many branch points, feed-forward and feedback controls — connects the activities of RB and p53. Disruption of this signalling network could be an essential feature of the life history of cancer cells.
This is a preview of subscription content,access via your institution
Access options
Subscription info for Japanese customers
We have a dedicated website for our Japanese customers. Please go tonatureasia.com to subscribe to this journal.
Prices may be subject to local taxes which are calculated during checkout




Similar content being viewed by others

p53 target ANKRA2 cooperates with RFX7 to regulate tumor suppressor genes
References
Weinberg, R. A. The retinoblastoma gene and cell cycle control.Cell81, 323–330 (1995).
Dyson, N. The regulation of E2F by pRB-family proteins.Genes Dev.12, 2245–2262 (1998).
Serrano, M., Hannon, G. J. & Beach, D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4.Nature366, 704–707 (1993).
Sherr, C. J. Cancer cell cycles.Science274, 1672–1677 (1996).
Levine, A. J. p53, the cellular gatekeeper for growth and division.Cell88, 323–331 (1997).
Giaccia, A. J. & Kastan, M. B. The complexity of p53 modulation: emerging patterns from diverging signals.Genes Dev.12, 2973–2983 (1998).
Sionov, R. V. & Haupt, Y. The cellular response to p53: the decision between life and death.Oncogene18, 6145–6157 (1999).
Bates, S. & Vousden, K. H. Mechanisms of p53-mediated apoptosis.Cell. Mol. Life Sci.55, 28–37 (1999).
Juven-Gershon, T. & Oren, M. Mdm2: the ups and downs.Mol. Med.5, 71–83 (1999).
Zhang, Y. & Xiong, Y. Control of p53 ubiquitination and nuclear export by MDM2 and ARF.Cell Growth Differ.12, 175–186 (2001).
Weber, J. D., Taylor, L. J., Roussel, M. F., Sherr, C. J. & Bar-Sagi, D. Nucleolar Arf sequesters Mdm2 and activates p53.Nature Cell. Biol.1, 20–26 (1999).
Honda, R. & Yasuda, H. Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.EMBO J.18, 22–27 (1999).
Llanos, S., Clark, P. A., Rowe, J. & Peters, G. Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus.Nature Cell Biol.3, 445–452 (2001).
Quelle, D. E., Zindy, F., Ashmun, R. A. & Sherr, C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest.Cell83, 993–1000 (1995).
Kamb, A. et al. A cell cycle regulator involved in genesis of many tumor types.Science264, 436–440 (1994).
Ruas, M. & Peters, G. The p16INK4a/CDKN2A tumor suppressor and its relatives.Biochem. Biophys. Acta Rev. Cancer1378, F115–F177 (1998).
Nevins, J. R. Toward an understanding of the functional complexity of the E2F and retinoblastoma families.Cell Growth Differ.9, 585–593 (1998).
Harbour, J. W. & Dean, D. C. The Rb/E2F pathway: expanding roles and emerging paradigms.Genes Dev.14, 2393–2409 (2000).
Roussel, M. F. The INK4 family of cell cycle inhibitors in cancer.Oncogene18, 5311–5317 (1999).
Lukas, J., Petersen, B. O., Holm, K., Bartek, J. & Helin, K. Deregulated expression of E2F family members induces S-phase entry and overcomes p16INK4a-mediated growth suppression.Mol. Cell. Biol.16, 1047–1057 (1996).
DeGregori, J., Leone, G., Miron, A., Jakoi, L. & Nevins, J. R. Distinct roles for E2F proteins in cell growth control and apoptosis.Proc. Natl Acad. Sci. USA94, 7245–7250 (1997).
Muller H. et al. E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis.Genes Dev.15, 267–285 (2001).
Humbert, P. O. et al.E2f3 is critical for normal cellular proliferation.Genes Dev.14, 690–703 (2000).Disruption of mouseE2f3, but notE2f1, reduces transcription of E2f-responsive genes and retards entry into S phase.
Ziebold, U., Reza, T., Caron, A. & Lees, J. A. E2F3 contributes both to the inappropriate proliferation and to the apoptosis arising inRb mutant embryos.Genes Dev.15, 386–391 (2001).
Lissy, N. A., Davis, P. K., Irwin, M., Kaelin, W. G. & Dowdy, S. F. A common E2F-1 and p73 pathway mediates cell death induced by TCR activation.Nature407, 642–645 (2000).
Irwin, M. et al. Role for the p53 homologue p73 in E2F-1-induced apoptosis.Nature407, 645–648 (2000).
Yamasaki, L. et al. Loss of E2F-1 reduces tumorigenesis and extends lifespan of Rb1+/− mice.Nature Genet.18, 360–364 (1998).
Pan, H. et al. Key roles for E2F1 in signaling p53-dependent apoptosis and cell division.Mol. Cell2, 283–292 (1998).
Tsai, K. et al. Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos.Mol. Cell2, 293–304 (1998).
Lipinski, M. M. & Jacks, T. The retinoblastoma gene family in differentiation and development.Oncogene18, 7873–7882 (1999).
Lukas, J. et al. Rb-dependent cell cycle inhibition by p16CDKN2A tumor suppressor.Nature375, 503–506 (1995).
Koh, J., Enders, G. H., Dynlacht, B. D. & Harlow, E. Tumour-derived p16 alleles encoding proteins defective in cell cycle inhibition.Nature375, 506–510 (1995).
Medema, R. H., Herrera, R. E., Lam, F. & Weinberg, R. A. Growth suppression by p16Ink4a requires functional retinoblastoma protein.Proc. Natl Acad. Sci. USA92, 6289–6293 (1995).
Sherr, C. J. & Roberts, J. M. CDK inhibitors: positive and negative regulators of G1-phase progression.Genes Dev.13, 1501–1512 (1999).
Krimpenfort, P., Quon, K. C., Mooi, W. J., Loonstra, A. & Berns, A. Loss of Cdkn2a (p16INK4a) confers susceptibility to metastatic melanoma in mice.Nature413, 83–86 (2001).
Sharpless, N. E. et al. Loss of p16INK4a with retention of p19ARF predisposes to tumourigenesis in mice.Nature413, 86–91 (2001).Specific disruption ofInk4a by point mutation (Ref.35) or by deletion of exon 1 (Ref.36), each with retention ofArf, enables definition of the role of p16Ink4a in the mouse. Although many features initially attributed to p16Ink4a instead reflectArf function,Ink4a does function as a tumour-suppressor gene in the mouse.
Latres, E. et al. Limited overlapping roles of p15INK4b and p18INK4c cell cycle inhibitors in proliferation and tumorigenesis.EMBO J.19, 3496–3506 (2000).
Herman, J. G., Jen, J., Merlo, A. & Baylin, S. B. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4b.Cancer Res.56, 722–727 (1996).
Zindy, F. et al. Control of spermatogenesis in mice by the cyclin D-dependent kinase inhibitors p18Ink4c and p19Ink4d.Mol. Cell. Biol.21, 3244–3255 (2001).
Zindy, F. et al. Postnatal neuronal proliferation in mice lacking Ink4d and Kip1 inhibitors of cyclin-dependent kinases.Proc. Natl Acad. Sci. USA96, 13462–13467 (1999).
Franklin, D. S., Godfrey, V. L., O'Brien, D. A., Deng, C. & Xiong, Y. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity.Mol. Cell. Biol.20, 6147–6158 (2000).
Serrano, M. et al. Role of the INK4a locus in tumor suppression and cell mortality.Cell85, 27–37 (1996).
Kamijo, T. et al. Tumor suppression at the mouseINK4a locus mediated by the alternative reading frame product p19ARF.Cell91, 649–659 (1997).
Zhang, S., Ramsay, E. S. & Mock, B. A.Cdkn2a, the cyclin-dependent kinase inhibitor gene encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus,Pctr1.Proc. Natl Acad. Sci. USA95, 2429–2434 (1998).
Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J. & Cleveland, J. L. Disruption of the ARF–Mdm2–p53 tumor suppressor pathway in Myc-induced lymphomagenesis.Genes Dev.13, 2658–2669 (1999).
Jacobs, J. J. L. et al. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF.Genes Dev.13, 2678–2690 (1999).
Schmitt, C. A., McCurrach, M. E., De Stanchina, E. & Lowe, S. W.INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53.Genes Dev.13, 2670–2677 (1999).
Carnero, A., Hudson, J. D., Price, C. M. & Beach, D. H. p16INK4a and p19ARF act in overlapping pathways in cellular immortalization.Nature Cell Biol.2, 148–155 (2000).
Chin, L. et al. Cooperative effects ofINK4a andras in melanoma susceptibilityin vivo.Genes Dev.11, 2822–2834 (1997).
Sherr, C. J. & DePinho, R. A. Cellular senescence: mitotic clock or culture shock.Cell102, 407–410 (2000).
Wright, W. E. & Shay, J. W. Cellular senescence as a tumor-protection mechanism: the essential role of counting.Curr. Opin. Genet. Dev.11, 98–103 (2001).
Sage, J. et al. Targeted disruption of the three Rb-related genes leads to loss of G1 control and immortalization.Genes Dev.14, 3037–3050 (2000).
Dannenberg, J.-H., van Rossum, A., Schuijff, L. & te Riele, H. Ablation of the retinoblastoma protein gene family deregulates G1 control causing immortalization and increased cell turnover under growth-restricting conditions.Genes Dev.14, 3051–3064 (2000).
Peeper, D. S., Dannenberg, J.-H., Douma, S., te Riele, H. & Bernards, R. Escape from premature senescence is not sufficient for oncogenic transformation by Ras.Nature Cell Biol.3, 198–203 (2001).References53 and54 show that whereas MEFs lacking Rb undergo senescence in culture, those lacking several Rb-family members seem to be immortal. Intriguingly, cells lacking Rb, p107 and p130 are resistant to growth arrest by p19Arf.
Randle, D. H., Zindy, F., Sherr, C. J. & Roussel, M. F. Differential effects of p19Arf and p16Ink4a loss on senescence of murine bone marrow-derived preB cells and macrophages.Proc Natl Acad Sci USA,98, 9654–9659 (2001).Like MEFs, mouse bone-marrow-derived pre-B cells that lackArf are immortal, whereas bone-marrow-derived macrophages must also silence theInk4a gene to become established as continuously growing cell lines.
Kiyono, T. et al. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells.Nature396, 84–88 (1998).
Brenner, A. J., Stampfer, M. R. & Aldaz, C. M. Increasedp16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity withp16 inactivation.Oncogene17, 199–205 (1998).
Ramirez, R. D. et al. Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions.Genes Dev.15, 398–403 (2001).Growing primary human keratinocytes and mammary epithelial cells over feeder layers in defined medium can prevent induction of p16Ink4a and enable their immortalization by introducing the telomerase catalytic subunit.
Zindy, F. et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization.Genes Dev.12, 2424–2433 (1998).
De Stanchina, E. et al. E1A signaling to p53 involves the p19ARF tumor suppressor.Genes Dev.12, 2434–2442 (1998).
Palmero, I., Pantoja, C. & Serrano, M. p19ARF links the tumor suppressor p53 to ras.Nature395, 125–126 (1998).
Radfar, A., Unnikrishnan, I., Lee, H.-W., DePinho, R. A. & Rosenberg, N. p19Arf induces p53-dependent apoptosis during Abelson virus-mediated pre-B cell transformation.Proc. Natl Acad. Sci. USA95, 13194–13199 (1998).
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., and Lowe, S. W. Oncogenicras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.Cell88, 593–602 (1997).
Ries, S. et al. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF.Cell103, 321–330 (2000).AlthoughRas triggersArf induction and thereby antagonizes Mdm2, Ras-dependent signalling through an Arf-independent pathway can lead to Mdm2 induction. In the absence ofArf, the latter pathway should dominate, making cells resistant to p53 induction following DNA damage.
Bates, S. et al. p14ARF links the tumour suppressors RB and p53.Nature395, 124–125 (1998).
Leone, G. et al. Myc requires distinct E2F activities to induce S phase and apoptosis.Mol. Cell8, 105–113 (2001).
Khan, S. H., Moritsugu, J. & Wahl, G. M. Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion.Proc. Natl Acad. Sci. USA97, 3266–3271 (2000).DNA damage activates p53 through bothArf-independent andArf-dependent signalling pathways, soArf loss affects the durability of the DNA-damage response.
Kastan, M. B. & Lim, D. The many substrates and functions of ATM.Nature Rev. Mol. Cell Biol.1, 179–186 (2000).
Maya, R. et al. ATM-dependent phosphorylation of Mdm2 on serine 395: role of p53 activation by DNA damage.Genes Dev.15, 1067–1077 (2001).
Lin, W.-C., Lin, F.-T. & Nevins, J. R. Selective induction of E2F1 in response to DNA damage mediated by ATM-dependent phosphorylation.Genes Dev.15, 1833–1844 (2001).The Atm kinase phosphorylates E2f1, enhancing its activity. This indicates a novel mechanism by which ATM might induce p53.
Jacobs, J. J., Kieboom, K., Marino, S., DePinho, R. A. & van Lohuizen, M. The oncogene and polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus.Nature397, 164–168 (1999).
Maestro, R. et al. Twist is a potential oncogene that inhibits apoptosis.Genes Dev.13, 2207–2217 (1999).
Jacobs, J. J. L. et al. Senescence bypass screen identified TBX2, which represses cdkn2a (p19ARF) and is amplified in a subset of human breast cancers.Nature Genet.26, 291–299 (2000).
Pantoja, C. & Serrano, M. Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras.Oncogene18, 4974–4982 (1999).
Kamijo, T. et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.Proc. Natl Acad. Sci. USA95, 8292–8297 (1998).
Stott, F. et al. The alternative product from the humanCDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2.EMBO J.17, 5001–5014 (1998).
Weber, J. D. et al. p53-independent functions of the p19ARF tumor suppressor.Genes Dev.14, 2358–2365 (2000).Mice lackingArf,Mdm2 andp53 show a broader spectrum of tumours than those lackingMdm2 andp53. Introduction of p19Arf into primary MEFs that lackArf,Mdm2 andp53 induces G1 arrest, albeit slowly. Arf must interact with proteins other than Mdm2.
Acknowledgements
The author gratefully thanks M. F. Roussel and B. Schulman for insightful comments on the manuscript. C. J. S. is an Investigator of Howard Hughes Medical Institute.
Author information
Authors and Affiliations
Department of Tumor Cell Biology, Howard Hughes Medical Institute, St Jude Children's Research Hospital, 332 North Lauderdale, Tennessee, 38105, Memphis, USA
Charles J. Sherr
- Charles J. Sherr
You can also search for this author inPubMed Google Scholar
Glossary
- E2F TRANSCRIPTION FACTOR
A heterodimeric transcription factor that is composed of an E2F subunit (1–6) and either DP-1 or DP-2.
- ARF
An alternative reading-frame protein ofINK4a/ARF. The locus encodes p19Arf in the mouse and p14ARF in humans.
- E3 UBIQUITIN PROTEIN LIGASE
The third enzyme in a series — the first two are designated E1 and E2 — that are responsible for ubiquitylation of target proteins. E3 enzymes provide platforms for binding E2 enzymes and specific substrates, thereby coordinating ubiquitylation of the selected substrates.
- DP-1 AND DP-2
Proteins that dimerize with E2F subunits, enabling E2F–DP complexes to bind to DNA.
- INK4 FAMILY
A family of genes that encode an inhibitor of CDK4. Four such genes — designated in order of discovery — areINK4a,INK4b,INK4c andINK4d. These encode polypeptides of 15–19 kDa and are designated p16INK4a, p15INK4b, p18INK4c and p19INK4d, respectively.
- CIP/KIP FAMILY
A family of genes that includes p21Cip1, p27Kip1 and p57Kip2. Cip, CDK-inhibitory protein; Kip, kinase-inhibitory protein.
- EXTRAMEDULLARY HAEMATOPOIESIS
Blood formation at sites outside of the bone marrow, usually in the spleen or liver.
- EARLY PASSAGE
Primary cells explanted into culture, when grown and serially transferred, eventually undergo replicative arrest. Cells at early passage maintain a more robust proliferative capacity, whereas those at late passage replicate less well.
- PLASMACYTOMA
A tumour mass, usually solitary, containing immunoglobulin-producing plasma cells. The presence of many such disseminated tumours, usually in bone, is called multiple myeloma.
- IMMUNOGLOBULIN PROMOTER–ENHANCER
Regulatory sequences of genes that encode heavy (μ) or light (κ or λ) immunoglobulin polypeptides that assemble to form antibodies. In B-cell tumours, these regulatory sequences are translocated and fused to other genes, including theMyc oncogene.
- HAPLO-INSUFFICIENCY
A state in which loss of only one of two alleles of a gene detectably disables its function.
- RHABDOMYOSARCOMA
Malignant tumour arising from skeletal muscle.
Rights and permissions
About this article
Cite this article
Sherr, C. TheINK4a/ARF network in tumour suppression.Nat Rev Mol Cell Biol2, 731–737 (2001). https://doi.org/10.1038/35096061
Issue Date:
This article is cited by
TYMS promotes genomic instability and tumor progression in Ink4a/Arf null background
- Maria V. Guijarro
- Akbar Nawab
- Maria Zajac-Kaye
Oncogene (2023)
ARF suppression by MYC but not MYCN confers increased malignancy of aggressive pediatric brain tumors
- Oliver J. Mainwaring
- Holger Weishaupt
- Fredrik J. Swartling
Nature Communications (2023)
Spontaneous p53 activation in middle-aged C57BL/6 mice mitigates the lifespan-extending adaptive response induced by low-dose ionizing radiation
- Masaoki Kohzaki
- Keiji Suzuki
- Ryuji Okazaki
npj Aging (2023)
Overlapping genes in natural and engineered genomes
- Bradley W. Wright
- Mark P. Molloy
- Paul R. Jaschke
Nature Reviews Genetics (2022)
p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases
- Jing Ni
- Sheheryar Kabraji
- Jean J. Zhao
Nature Communications (2022)